User login
The past decade has brought tremendous progress in the treatment of HR+/HER2- advanced breast cancer. The use of newer targeted agents, including PI3K, mTOR, and CDK4/6 inhibitors, in combination with endocrine therapy (ET) may prove a valuable strategy to overcome ET resistance and further extend patient survival.
In this ReCAP, Dr Richard Finn, of the Geffen School of Medicine at UCLA, discusses the growing body of research into CDK4/6 inhibition, PI3K inhibition, and mTOR inhibition, with and without ET. He touches on findings from the EMERALD, MAINTAIN, and monarchE studies to highlight evidence supporting that these targeted agents, in combination with ET, may improve outcomes for patients with advanced disease.
He comments on approaches to sequencing ET and novel agents for patients with recurrence or disease progression, taking into consideration their unique tumor burden, pace of disease, and possible gene mutations. Dr Finn concludes by advising that clinical trial enrollment can provide high-risk patients access to the newest treatments.
--
Professor, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, Los Angeles, California
Richard S. Finn, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Bayer; CStone; Eisai; Exelixis; Eli Lilly; Pfizer; Merck; Roche; Genentech; Jiangsu Hengrui
Serve(d) as a speaker or a member of a speakers bureau for: Genentech Institution received research grant from: Bayer; Eli Lilly; Eisai; Pfizer; Roche; Genentech
Received income in an amount equal to or greater than $250 from: AstraZeneca; Bayer; CStone; Eisai; Exelixis; Eli Lilly; Pfizer; Merck; Roche; Genentech; Jiangsu Hengrui
The past decade has brought tremendous progress in the treatment of HR+/HER2- advanced breast cancer. The use of newer targeted agents, including PI3K, mTOR, and CDK4/6 inhibitors, in combination with endocrine therapy (ET) may prove a valuable strategy to overcome ET resistance and further extend patient survival.
In this ReCAP, Dr Richard Finn, of the Geffen School of Medicine at UCLA, discusses the growing body of research into CDK4/6 inhibition, PI3K inhibition, and mTOR inhibition, with and without ET. He touches on findings from the EMERALD, MAINTAIN, and monarchE studies to highlight evidence supporting that these targeted agents, in combination with ET, may improve outcomes for patients with advanced disease.
He comments on approaches to sequencing ET and novel agents for patients with recurrence or disease progression, taking into consideration their unique tumor burden, pace of disease, and possible gene mutations. Dr Finn concludes by advising that clinical trial enrollment can provide high-risk patients access to the newest treatments.
--
Professor, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, Los Angeles, California
Richard S. Finn, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Bayer; CStone; Eisai; Exelixis; Eli Lilly; Pfizer; Merck; Roche; Genentech; Jiangsu Hengrui
Serve(d) as a speaker or a member of a speakers bureau for: Genentech Institution received research grant from: Bayer; Eli Lilly; Eisai; Pfizer; Roche; Genentech
Received income in an amount equal to or greater than $250 from: AstraZeneca; Bayer; CStone; Eisai; Exelixis; Eli Lilly; Pfizer; Merck; Roche; Genentech; Jiangsu Hengrui
The past decade has brought tremendous progress in the treatment of HR+/HER2- advanced breast cancer. The use of newer targeted agents, including PI3K, mTOR, and CDK4/6 inhibitors, in combination with endocrine therapy (ET) may prove a valuable strategy to overcome ET resistance and further extend patient survival.
In this ReCAP, Dr Richard Finn, of the Geffen School of Medicine at UCLA, discusses the growing body of research into CDK4/6 inhibition, PI3K inhibition, and mTOR inhibition, with and without ET. He touches on findings from the EMERALD, MAINTAIN, and monarchE studies to highlight evidence supporting that these targeted agents, in combination with ET, may improve outcomes for patients with advanced disease.
He comments on approaches to sequencing ET and novel agents for patients with recurrence or disease progression, taking into consideration their unique tumor burden, pace of disease, and possible gene mutations. Dr Finn concludes by advising that clinical trial enrollment can provide high-risk patients access to the newest treatments.
--
Professor, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, Los Angeles, California
Richard S. Finn, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Bayer; CStone; Eisai; Exelixis; Eli Lilly; Pfizer; Merck; Roche; Genentech; Jiangsu Hengrui
Serve(d) as a speaker or a member of a speakers bureau for: Genentech Institution received research grant from: Bayer; Eli Lilly; Eisai; Pfizer; Roche; Genentech
Received income in an amount equal to or greater than $250 from: AstraZeneca; Bayer; CStone; Eisai; Exelixis; Eli Lilly; Pfizer; Merck; Roche; Genentech; Jiangsu Hengrui
